Suven Life Sciences Ltd has received product patents for new chemical entities (NCEs) – used in the treatment of disorders associated with neurodegenerative diseases – from Israel, Macau and USA. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of five granted patents from Israel, four from Macau and 21 from US.
With these new patents, Suven has a total of five granted patents from Israel, four from Macau and 21 from US.